The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Mult Scler Relat Disord
; 45: 102437, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-688895
ABSTRACT
We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Respiratory Distress Syndrome
/
Coronavirus Infections
/
RhoA GTP-Binding Protein
/
Enzyme Inhibitors
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS